Retrospective analysis of 264 multiple myeloma patients

Geng,Chuanying; Liu,Nian; Yang,Guangzhong; Liu,Aijun; Leng,Yun; Wang,Huijuan; Li,Lihong; Wu,Yin; Li,Yanchen; Chen,Wenming

doi:10.3892/ol.2012.1018

February 2013 Volume 5 Issue 2

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

February 2013 Volume 5 Issue 2

Full Size Image

Article

Retrospective analysis of 264 multiple myeloma patients

Authors:
- Chuanying Geng
- Nian Liu
- Guangzhong Yang
- Aijun Liu
- Yun Leng
- Huijuan Wang
- Lihong Li
- Yin Wu
- Yanchen Li
- Wenming Chen
View Affiliations / Copyright

Affiliations: Department of Hematology, Beijing Chaoyang Hospital, Capital Medical University, Beijing 100020, P.R. China
Pages: 707-713
|
Published online on: November 9, 2012

https://doi.org/10.3892/ol.2012.1018
Expand metrics +

Abstract

Multiple myeloma (MM) is the second most common hematological malignancy in China. However, there are only a small number of large cohort studies demonstrating the clinical features of newly diagnosed MM. In the present study, 264 newly diagnosed MM patients from the Beijing Chaoyang Hospital were retrospectively analyzed. The median patient age was 59 years (range, 28‑84) and the most common monoclonal protein (42%) was the IgG subtype. Of the 49 patients detected by FISH, 10.2, 2.0 and 12.2% demonstrated del(17p), t(14;16) and t(4;14), respectively. In total, 228 (86%) patients achieved either a complete response (CR), a very good partial response (VGPR) or a partial response (PR). The overall response rate (ORR) in non-autologous stem cell transplantation (non‑ASCT) patients was 83.0%, with 48 (18.2%), 7 (2.7%) and 121 (45.8%) patients achieving CR, VGPR and PR, respectively. ASCT patients achieved at least a PR prior to ASCT, and ASCT was not able to increase the ORR (P=0.55). Non‑ASCT patients who received bortezomib-based regimens demonstrated an improved ORR compared with those who received regimens that did not contain bortezomib (92.3% vs. 75.8%; P<0.05). With a median follow-up time of 20 months, the estimated median progression-free survival (PFS) and overall survival (OS) times were 27.6 and 61.0 months, respectively. The OS time of patients with high-risk cytogenetic abnormality, del(17p), t(14;16) and t(4;14), was shorter compared with that of other patients (30.2 months vs. not reached, P=0.029). Patients who achieved a CR/VGPR in the ASCT group demonstrated a greater OS time compared with non-ASCT patients (P=0.031). Relapsed patients who received bortezomib-based regimens did not demonstrate a longer survival time post-relapse compared with those who received non-bortezomib-based regimens (26.5 months vs. 10.5 months; P=0.271). The current study presented the clinical characteristics of MM patients who were initially treated at the Beijing Chaoyang Hospital. Bortezomib-based regimens and ASCT were able to improve the OS of MM patients.

View Figures

View References

1.	Raab MS, Podar K, Breitkreutz I, Richardson PG and Anderson KC: Multiple myeloma. Lancet. 374:324–339. 2009. View Article : Google Scholar
2.	Rajkumar SV: Multiple myeloma: 2011 update on diagnosis, risk-stratification, and management. Am J Hematol. 86:57–65. 2011. View Article : Google Scholar : PubMed/NCBI
3.	Kyle RA and Rajkumar SV: Multiple myeloma. Blood. 111:2962–2972. 2008. View Article : Google Scholar : PubMed/NCBI
4.	Kyle RA, Gertz MA, Witzig TE, et al: Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc. 78:21–33. 2003. View Article : Google Scholar : PubMed/NCBI
5.	Durie BG, Harousseau JL, Miguel JS, et al: International uniform response criteria for multiple myeloma. Leukemia. 20:1467–1473. 2006. View Article : Google Scholar : PubMed/NCBI
6.	Becker N: Epidemiology of multiple myeloma. Recent Results Cancer Res. 183:25–35. 2011. View Article : Google Scholar
7.	Tuscano JM: Multiple myeloma: epidemiology and therapeutic options. Manag Care. 17:9–15. 2008.PubMed/NCBI
8.	Mileshkin L, Biagi JJ, Mitchell P, et al: Multicenter phase 2 trial of thalidomide in relapsed/refractory multiple myeloma: adverse prognostic impact of advanced age. Blood. 102:69–77. 2003. View Article : Google Scholar : PubMed/NCBI
9.	Choi JH, Yoon JH and Yang SK: Clinical value of new staging systems for multiple myeloma. Cancer Res Treat. 39:171–174. 2007. View Article : Google Scholar : PubMed/NCBI
10.	Greipp PR, San Miguel J, Durie BG, et al: International staging system for multiple myeloma. J Clin OncoI. 23:3412–3420. 2005. View Article : Google Scholar : PubMed/NCBI
11.	Avet-Loiseau H, Attal M, Moreau P, et al: Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome. Blood. 109:3489–3495. 2007.PubMed/NCBI
12.	Gutiérrez NC, Castellanos MV, Martín ML, et al: Prognostic and biological implications of genetic abnormalities in multiple myeloma undergoing autologous stem cell transplantation: t(4;14) is the most relevant adverse prognostic factor, whereas RB deletion as a unique abnormality is not associated with adverse prognosis. Leukemia. 21:143–150. 2007.
13.	Nadal E, Giné E, Bladé J, et al: High-dose therapy/autologous stem cell transplantation in patients with chemosensitive myeloma: predictors of complete remission. Bone Marrow Transplant. 33:61–64. 2004. View Article : Google Scholar : PubMed/NCBI
14.	Lahuerta JJ, Mateos MV, Martínez-López J, et al: Influence of pre- and post-transplantation responses on outcome of patients with multiple myeloma: sequential improvement of response and achievement of complete response are associated with longer survival. J Clin Oncol. 26:5775–5782. 2008. View Article : Google Scholar
15.	van de Velde HJ, Liu X, Chen G, et al: Complete response correlates with long-term survival and progression-free survival in high-dose therapy in multiple myeloma. Haematologica. 92:1399–1406. 2007.PubMed/NCBI
16.	Delforge M: Bortezomib for previously untreated multiple myeloma. Expert Opin Pharmacother. 12:2553–2564. 2011. View Article : Google Scholar : PubMed/NCBI
17.	Terpos E, Roussou M and Dimopoulos MA: Bortezomib in multiple myeloma. Expert Opin Drug Metab Toxicol. 4:639–654. 2008. View Article : Google Scholar

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

Retrospective analysis of 264 multiple myeloma patients

This article is mentioned in:

Abstract

Figure 1

Figure 2

Figure 3

Figure 4

Related Articles